Edition:
United Kingdom

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

17.58USD
8:40pm GMT
Change (% chg)

$0.98 (+5.90%)
Prev Close
$16.60
Open
$16.46
Day's High
$17.76
Day's Low
$16.36
Volume
31,297
Avg. Vol
--
52-wk High
$24.50
52-wk Low
$16.11

Latest Key Developments (Source: Significant Developments)

Deciphera Pharmaceuticals Q3 loss $5.85 per share​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Deciphera Pharmaceuticals Inc : :Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights.Qtrly loss $5.85 per share​.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.  Full Article

New Leaf Venture reports 12.9 pct stake in Deciphera Pharmaceuticals
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :New Leaf Venture Management III LLC reports 12.9 percent stake in Deciphera Pharmaceuticals as of Oct 2 - SEC filing‍​.  Full Article

Viking Global Investors reports 8.1 pct passive stake in Deciphera Pharmaceuticals
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :Viking Global Investors LP reports 8.1 percent passive stake in Deciphera Pharmaceuticals LLC ‍​as of Oct 2 - SEC filing‍​.  Full Article

Deciphera Pharmaceuticals prices initial public offering of 7.5 mln shares at $17 per share
Thursday, 28 Sep 2017 

Sept 27 (Reuters) - :Deciphera Pharmaceuticals announces pricing of initial public offering.Deciphera Pharmaceuticals announced pricing of initial public offering of 7.5 million shares of stock at public offering price of $17 per share.  Full Article

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage: